Relay Therapeutics R&D head sells 8,530 shares

Rhea-AI Filing Summary

Relay Therapeutics, Inc. (RLAY) reported that Donald A. Bergstrom, President, R&D, sold 8,530 shares of common stock on September 8, 2026 in an open-market or private transaction at a weighted average price of $18.97 per share, under a Rule 10b5-1 trading plan adopted on October 30, 2025. After this sale, he directly holds 399,130 shares, including 10,025 shares underlying restricted stock units.

Insider Trade Summary 10b5-1

Net Seller: 8,530 shares

Net Sell 1 txn

Insider Bergstrom Donald A

Role President, R&D

Sold 8,530 shs ($162K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2, F3	8,530	$18.97	$162K

Holdings After Transaction: Common Stock — 399,130 shares (Direct)

Footnotes (3)

1. F1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.
2. F2. This transaction was executed in multiple trades at prices ranging from $18.56 to $19.24. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
3. F3. Includes 10,025 shares underlying restricted stock units.

Key Figures

Shares sold: 8,530 shares Weighted average sale price: $18.97 per share Shares held after transaction: 399,130 shares +2 more

5 metrics

Shares sold 8,530 shares Common stock sale by Donald A. Bergstrom on September 8, 2026

Weighted average sale price $18.97 per share Open-market or private sale on September 8, 2026; trades ranged from $18.56 to $19.24

Shares held after transaction 399,130 shares Direct holdings by Donald A. Bergstrom following the September 8, 2026 sale

Restricted stock units included in holdings 10,025 shares underlying RSUs Portion of the 399,130 post-transaction shares

Rule 10b5-1 plan adoption date October 30, 2025 Trading plan under which the September 8, 2026 sale was effected

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, restricted stock units

3 terms

Rule 10b5-1 trading plan regulatory

"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported above reflects the weighted average sale price"

restricted stock units financial

"Includes 10,025 shares underlying restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Relay Therapeutics (RLAY) disclose for Donald A. Bergstrom?

Relay Therapeutics disclosed that Donald A. Bergstrom, President, R&D, sold 8,530 shares of common stock on September 8, 2026 in a reported open-market or private sale transaction.

At what price were the RLAY shares sold in this Form 4 filing?

The reported sale was executed at a weighted average price of $18.97 per share, with individual trade prices ranging from $18.56 to $19.24, according to the transaction footnote.

How many Relay Therapeutics (RLAY) shares does Donald A. Bergstrom hold after the sale?

Following the reported transaction, Donald A. Bergstrom directly holds 399,130 shares of Relay Therapeutics common stock, which includes 10,025 shares underlying restricted stock units.

Was the RLAY insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states the transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Donald A. Bergstrom on October 30, 2025, indicating the trades were pre-arranged under that plan.

How many Relay Therapeutics (RLAY) shares were sold in total in this Form 4?

The Form 4 reports a single sale transaction totaling 8,530 shares of Relay Therapeutics common stock, with no reported purchases or derivative exercises in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 04:17 PM EDT Accepted by SEC EDGAR 09/09/2026 - 04:17 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bergstrom Donald A

(Last) (First) (Middle)

C/O RELAY THERAPEUTICS, INC.

60 HAMPSHIRE STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Relay Therapeutics, Inc. [ RLAY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, R&D

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/08/2026		S(1)		8,530	D	$18.97(2)	399,130(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.

2. This transaction was executed in multiple trades at prices ranging from $18.56 to $19.24. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. Includes 10,025 shares underlying restricted stock units.

	/s/ Soo-Yeun Lim, as Attorney-in-Fact	09/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)